Glenmark Pharmaceuticals' antiviral drug Favipiravir has been approved by DCGI. The drug reduces viral load but cannot cure patients immediately.
On June 19, 2020, Glenmark Pharmaceuticals received approval for the marketing and manufacturing of antiviral drug Favipiravir from the Drugs Controller General of India(DCGI). The oral drug would be sold under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 symptoms.
The drug manufacturer said, Favipiravir showed clinical improvement of up to 88 percent in mild to moderate COVID-19 cases and offered a rapid reduction in viral load within four days. The drug was also used in Russia, Japan, and China to treat COVID-19 patients successfully.
It can be used on patients with comorbid conditions such as diabetes and heart disease but is not recommended for those suffering from severe kidney or liver ailments or pregnant and lactating women.
FabiFlu tablets would be available for sale in hospitals and retail pharmacies across the country by early next week. It should be administered under strict medical supervision and would not be available over-the-counter. It would be sold in a pack of 34 oral tablets of 200 mg each for ₹3,500, and the cost of the 14-day treatment will be an estimated ₹14,000.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.